ANAB - CIK 0001370053
ANAPTYSBIO, INC (ANAB) reported net income of -$13.23M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$13.23M | +90.9% |
| FY 2024 | -$145.23M | +11.2% |
| FY 2023 | -$163.62M | -27.1% |
| FY 2022 | -$128.72M | -122.7% |
| FY 2021 | -$57.80M | -190.0% |
| FY 2020 | -$19.93M | +79.5% |
| FY 2019 | -$97.34M | -57.9% |
| FY 2018 | -$61.66M | -105.0% |
| FY 2017 |
ANAPTYSBIO, INC (ANAB) reported net income of -$13.23M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2015 and fiscal 2025, ANAPTYSBIO, INC's net income declined from -$5.41M to -$13.23M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$30.07M |
| -606.0% |
| FY 2016 | -$4.26M | +21.2% |
| FY 2015 | -$5.41M | - |